Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.840
+0.020 (0.71%)
At close: Aug 17, 2026, 4:00 PM EDT
2.880
+0.040 (1.41%)
Pre-market: Aug 18, 2026, 8:06 AM EDT

Editas Medicine Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
47.0140.5232.3178.1219.7125.54
Revenue Growth
20.83%25.39%-58.64%296.32%-22.83%-71.85%
Gross Profit
-37.95-49.43-166.93-99.53-155.25-116.96
Operating Income
-83.46-99.34-238.92-169.18-225.95-193.15
Net Income
-73.95-160.06-237.09-153.22-220.43-192.5
Earnings Per Share
-0.73-1.80-2.88-2.02-3.21-2.85
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
211.65146.65269.91427.14437.37619.92
Total Debt
15.5118.135.0336.5443.9526.38
Net Cash (Debt)
196.13128.54234.88390.6393.43593.54
Net Cash Growth
24.64%-45.27%-39.87%-0.72%-33.72%22.22%
Net Cash Per Share
1.941.452.855.145.738.78

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-119.86-165.24-210.28-132.18-177.35-163.8
Capital Expenditures
-0.69-0.61-8.83-4.72-4.12-7.98
Free Cash Flow
-120.55-165.85-219.11-136.9-181.47-171.78
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-80.75%-122.00%--127.40%--
Operating Margin
-177.56%-245.15%-739.37%-216.56%-1146.26%-756.13%
Pretax Margin
-157.32%-395.01%-733.72%-196.13%-1118.26%-753.61%
Profit Margin
-157.32%-395.01%-733.72%-196.13%-1118.26%-753.61%
FCF Margin
-256.46%-409.30%-678.06%-175.23%-920.59%-672.49%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
9.284.943.2410.5930.2770.31